Tag: medicine
-
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
As the world increasingly faces the complexities of autoimmune and neurodegenerative diseases, new medical advancements are crucial to better serve patients’ needs. Enter Bionxt Solutions Inc. (BNXT.C), a bioscience innovator making moves with its groundbreaking sublingual (under-the-tongue) drug delivery technology. This technology, now in the process of securing national-level patents globally, represents a shift from…
-
Alpha Cognition Inc (ACOG.C) has navigated the Alzheimers FDA process like a champ
People really don’t like pharma companies in Canada. We’ve had some monster megacorporations come out of Canada in the pharma space, and the biotech space, and a lot of them turned out to be robber baron villains with twirly moustaches looking to monetize mom’s ailments in ways that ensure the highest possible return in the…
-
![Revive Therapeutics (RVV.C) finds multiple research options moving forward]()
Revive Therapeutics (RVV.C) finds multiple research options moving forward
In Canada, if you look backwards over the timeline, you’ll often find public companies have been other things back in the day. Risen, fallen, tapped out, rolled back, reemerged as a whole new thing. Sometimes this happens several times before a business model catches. Revive Therapeutics (RVV.C) is that rare Canadian smallcap that, while it…
-
![Lucy Loves Luchre: Medexus Pharmaceuticals (MDP.T) is growing fast, keeping the bottom line trim]()
Lucy Loves Luchre: Medexus Pharmaceuticals (MDP.T) is growing fast, keeping the bottom line trim
Hey y’all, Lucy Copperpot back for more analysis of Equity.Guru companies – this one is no longer on the client list, but I asked for permission to dig in anyway because I really think a ton of risk has been removed from Medexus Pharmaceuticals (MDP.T) that the market hasn’t factored in, and that’s a real…
-
![The Core Story: Medexus Pharmaceutical (MDP.T) just grows and grows]()
The Core Story: Medexus Pharmaceutical (MDP.T) just grows and grows
Continuing out Core Story program, today’s exploration is a company we just can’t get enough of, Medexus Pharmaceuticals (MDP.T). CEO Ken D’Entremont has nailed his milestones the last 18 months, continued running revenues up, kept expenses low, and restructured convertible debt to remain in control os his company’s direction going forward. They’ve blasted through a…
-
![Predictmedix (PMED.C) engages global investment bank to prep for NASDAQ listing]()
Predictmedix (PMED.C) engages global investment bank to prep for NASDAQ listing
The Nasdaq Exchange has 3,300 listed stocks including giants such as Apple (AAPL.Q), Google (GOOG.Q), Microsoft (MSFT.Q), Oracle (ORCL.Q), Amazon (AMZN.Q), and Intel (INTC.Q).
-
![Diagnos (ADK.V) uses AI and telemedicine to scan your eye for health issues in 16 countries]()
Diagnos (ADK.V) uses AI and telemedicine to scan your eye for health issues in 16 countries
In a world where companies toss the term ‘artificial intelligence’ around whenever the office intern figures out how to get a spreadsheet pie chart to update automatically, it’s nice to see a company utilizing actual AI and machine learning in a manner that involves actual intelligence and learning. Diagnos (ADK.V) is a health tech deal…
-
![Perimeter Medical Imaging AI (PINK.V) technology advances as ACS reports 2.3 million new breast cancer cases]()
Perimeter Medical Imaging AI (PINK.V) technology advances as ACS reports 2.3 million new breast cancer cases
In 25% of Breast Lumpectomy surgeries, cancerous material is left behind. With current technology, the surgeon needs to wait about a week, to see if he’s got all the cancerous material.
-
Does Core One Labs (COOL.C) have a solution for psilocybin’s dosing problem?
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and addictions.
-
Core One Labs (COOL.C) acquires 100% of a synthetic psilocybin company
“This transaction will significantly enhance Core One Labs’ ability to innovate our psychedelic drug development program,” stated Joel Shacker, CEO of Core Labs.
